SANA Live signals | Maximize Profits with Getagraph.com

BUY 157442 min ago

@ $7.22

Issued: 14 Feb 2024 @ 15:45

Return: 3.95%

Previous signal: Feb 13 - 14:34

Previous signal: Sell

Return: 12.56 %

Live Chart Being Loaded With Signals

Commentary (31 May 2024 @ 16:00):

Stats
Today's Volume	2.49M
Average Volume	1.71M
Market Cap	1.66B
EPS	$0 ( 2024-05-13 )
Next earnings date	( $-0.270 ) 2024-08-01
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.93
ATR14	$0.00800 (0.11%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-05	Bishop Hans Edgar	Buy	2 774	Common Stock
2024-04-01	Fmr Llc	Buy	0	Common Stock
2024-03-08	Yang Patrick Y	Sell	25 000	Common Stock
2024-03-07	Williams Douglas E	Buy	301 875	Stock Option (Right to Buy)
2024-03-07	Williams Douglas E	Buy	67 083	Restricted Stock Units

INSIDER POWER
6.51
Last 97 transactions
Buy: 15 455 910 \| Sell: 11 982 863

Volume Correlation

Long: -0.46 (neutral)

Short: -0.44 (neutral)

Signal:(34.821) Neutral

Sana Biotechnology, Inc. Correlation

10 Most Positive Correlations
MRUS	0.905
LPLA	0.899
FLEX	0.897
CLBT	0.888
MOR	0.888
REYN	0.883
ADSE	0.882
EQ	0.877
MACK	0.876
MEDP	0.872

10 Most Negative Correlations
OMCL	-0.912
BIOL	-0.909
CYAN	-0.909
CAR	-0.903
UTMD	-0.899
WTER	-0.894
SSRM	-0.894
QLYS	-0.89
EGAN	-0.887
FINW	-0.884

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Sana Biotechnology, Inc. Correlation - Currency/Commodity

-0.21
( neutral )

-0.19
( neutral )

0.00
( neutral )

0.26
( neutral )

0.31
( neutral )

Sana Biotechnology, Inc. Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-30.87M (0.00 %)
EPS:	$-1.460

FY	2023
Revenue:	$0
Gross Profit:	$-30.87M (0.00 %)
EPS:	$-1.460

FY	2022
Revenue:	$0
Gross Profit:	$-27.73M (0.00 %)
EPS:	$-1.410

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-1.958

Financial Reports:

No articles found.

Sana Biotechnology, Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Sana Biotechnology, Inc.

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.